Welcome to Nektar’s Clinical Resources page. Here you can learn about our cancer research and development activities and our goal to potentially harness the immune system in the fight against cancer.
Please click on the thumbnails below to access the PDFs of the documents. If you have any questions, please contact email@example.com.
NKTR-255 is an investigational IL-15 agonist that is designed to engage the IL-15 pathway to increase both NK cell proliferation and activation and proliferation and survival of CD8+ T cells.
Multiple Myeloma and Non-Hodgkin's Lymphoma:
Relapsed or Refractory Solid Tumors:
Bempegaldesleukin (BEMPEG; NKTR-214):
In April 2022, Nektar Therapeutics and Bristol Myers Squibb announced that the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. These studies and all other ongoing studies in the program will be discontinued, allowing patients and their physicians to consider standard of care treatment options for their specific conditions.
Skin Cancer (1L Metastatic Melanoma and Adjuvant Melanoma):
A phase 3, randomized, open-label study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients with previously untreated, unresectable or metastatic melanoma
Bladder Cancer (1L Metastatic Urothelial Carcinoma (mUC) and Muscle Invasive Bladder Cancer (MIBC)):
A phase 2, single-arm study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) in cisplatin-ineligible, locally advanced or metastatic urothelial cancer